PMID- 29982601
OWN - NLM
STAT- MEDLINE
DCOM- 20181001
LR  - 20221207
IS  - 1465-3621 (Electronic)
IS  - 0368-2811 (Linking)
VI  - 48
IP  - 9
DP  - 2018 Sep 1
TI  - Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in 
      Japanese women.
PG  - 794-798
LID - 10.1093/jjco/hyy095 [doi]
AB  - OBJECTIVE: The present study aimed to clarify the clinicopathological features, 
      including the level of p53 protein expression and BRCA mutations, of primary 
      fallopian tube cancer (PFTC) in Japanese women. METHODS: A multicenter clinical 
      survey was conducted at three Japanese institutions. Clinical data in patients 
      with PFTC between 1998 and 2016 were collected. Immunohistochemical staining of 
      p53 and BRCA mutation analysis by exome sequence using paraffin-embedded surgical 
      resected specimens were performed. RESULTS: A total of 40 patients with PFTC were 
      enrolled in the study. The median age was 58 years (range: 38-78 years); 31 
      patients were menopausal. Thirty-four (85.0%) patients were diagnosed with serous 
      adenocarcinoma (high grade, 33; low grade, 1). PFTC was classified into ampulla 
      type, fimbriae type and undeterminable type by tumor-occupying lesion; ampulla 
      type and fimbriae type occurred with the same frequency. Among 30 patients with 
      high-grade serous adenocarcinoma, 6 patients showed germline mutations of BRCA1 
      (stop-gain 4 and frameshift deletion 2) and 2 patients showed germline mutation 
      of BRCA2 (stop-gain 1 and frameshift deletion 1). However, only 1 patient had 
      familial history of breast or ovarian cancer. Patients with BRCA mutations in the 
      germline were frequently observed in ampulla type and FIGO stage I/II cancers, 
      but no significant difference in the frequency of p53 overexpression and overall 
      survival was observed. CONCLUSIONS: Among Japanese patients with PFTC, 26.7% 
      presented with BRCA mutations in the germline. Additionally, p53 was important 
      for the carcinogenesis in fallopian tubes, independent of the specific BRCA 
      mutation.
FAU - Sakurada, Shoko
AU  - Sakurada S
AD  - Department of Obstetrics and Gynecology, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Watanabe, Yoh
AU  - Watanabe Y
AD  - Department of Obstetrics and Gynecology, Tohoku Medical and Pharmaceutical 
      University, Sendai, Japan.
AD  - Clinical Research, Innovation and Education Center, Tohoku University Hospital, 
      Sendai, Japan.
FAU - Tokunaga, Hideki
AU  - Tokunaga H
AD  - Department of Obstetrics and Gynecology, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Takahashi, Fumiaki
AU  - Takahashi F
AD  - Clinical Research, Innovation and Education Center, Tohoku University Hospital, 
      Sendai, Japan.
FAU - Yamada, Hidekazu
AU  - Yamada H
AD  - Department of Gynecology, Miyagi Cancer Center, Sendai, Japan.
FAU - Takehara, Kazuhiro
AU  - Takehara K
AD  - Department of Gynecology, Shikoku Cancer Center, Matsuyama, Japan.
FAU - Yaegashi, Nobuo
AU  - Yaegashi N
AD  - Department of Obstetrics and Gynecology, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
RN  - 0 (BRCA2 Protein)
RN  - 0 (BRCA2 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Asian People/*genetics
MH  - BRCA1 Protein/*genetics
MH  - BRCA2 Protein/*genetics
MH  - Cystadenocarcinoma, Serous/genetics
MH  - Fallopian Tube Neoplasms/*genetics/*pathology
MH  - Fallopian Tubes/pathology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Mutation/*genetics
EDAT- 2018/07/10 06:00
MHDA- 2018/10/03 06:00
CRDT- 2018/07/09 06:00
PHST- 2018/01/08 00:00 [received]
PHST- 2018/06/09 00:00 [accepted]
PHST- 2018/07/10 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2018/07/09 06:00 [entrez]
AID - 5047926 [pii]
AID - 10.1093/jjco/hyy095 [doi]
PST - ppublish
SO  - Jpn J Clin Oncol. 2018 Sep 1;48(9):794-798. doi: 10.1093/jjco/hyy095.